1. Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202:592–8.
2. Gravas SC, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Guidelines Associates: Karavitakis M, Kyriazis I, Malde S, Sakalis V, Umbach R. EAU-Guidelines on Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)—Update March. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts.
3. Sahakyan Y, Erman A, Bhojani N, Chughtai B, Zorn KC, Sander B, et al. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00561-2.
4. Carbonara U, Osardu RK, Cisu TI, Balthazar A, Crocerossa F, Autorino R. Robot-assisted simple prostatectomy for giant benign prostatic hyperplasia. Cent Eur J Urol. 2020;73:383–4.
5. Banapour P, Patel N, Kane CJ, Cohen SA, Parsons JK. Robotic-assisted simple prostatectomy: a systematic review and report of a single institution case series. Prostate Cancer Prostatic Dis. 2014;17:1–5.